KEGG   DRUG: AvelumabHelp
Entry
D10817                      Drug                                   

Name
Avelumab (USAN);
Avelumab (genetical recombination) (JAN);
Bavencio (TN)
Product
Sequence
(Heavy chain)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS IYPSGGITFY
ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK LGTVTTVDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI YDVSNRPSGV
SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV FGTGTKVTVL GQPKANPTVT
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
(Disulfide bridge: H22-H96, H147-H203, H223-L215, H2229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'147-H'203, H'223-L'215, H'264-H'324, H'370-H'428, L22-L90, H138-L197, L'22-L'90, L'138-L'197)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
Therapeutic category: 4291
ATC code: L01XC31
Product: D10817<JP/US>
Efficacy
Antineoplastic, Immunomodulator, Anti-PD-L1 antibody
  Disease
Merkel cell carcinoma [DS:H01555]
Urothelial carcinoma [DS:H00022]
Comment
Monoclonal antibody
Target
PDL1 (CD274) [HSA:29126] [KO:K06745]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC31 Avelumab
      D10817  Avelumab (USAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10817  Avelumab (USAN); Avelumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D10817  Avelumab (USAN) <JP/US>
Antineoplastics [br08340.html]
 D10817
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10817
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10817
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10817
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10817
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10817
BRITE hierarchy
Other DBs
CAS: 1537032-82-8
PubChem: 319902617
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system